Infliximab Versus Vedolizumab in Outpatient Treatment of Immune Checkpoint Inhibitor Colitis

被引：0
|
作者：
Joseph, Joel A. [1 ]
Townsend, Matthew J. [2 ]
Somappa, Aakash K. [1 ]
Sack, Jordan [3 ]
Leboeuf, Nicole R. [4 ]
Sharon, Elad [4 ]
Grover, Shilpa [3 ]
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[4] Harvard Med Sch, Dana Farber Brigham Canc Ctr, Boston, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001029268.66368.a0
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S225
引用
收藏
页码：S164 / S165
页数：2
相关论文
共 50 条
  • [1] Randomized Clinical Trial of Infliximab Versus Vedolizumab for Immune Checkpoint Inhibitor Related Colitis
    Wang, Yinghong
    Varatharajalu, Krishnavathana
    Shatila, Malek
    Cruz, Carolina Colli
    Junek, Kristin
    Silva, Ninoska
    Thomas, Anusha
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S250 - S250
  • [2] RANDOMIZED CLINICAL TRIAL OF INFLIXIMAB VERSUS VEDOLIZUMAB FOR IMMUNE CHECKPOINT INHIBITOR RELATED COLITIS
    Wang, Yinghong
    Varatharajalu, Krishnavathana
    Shatila, Malek
    Thomas, Anusha Shirwaikar
    Junek, Kristin
    Silva, Ninoska
    Msaouel, Pavlos
    Siddiqui, Bilal
    Wang, Jianbo
    Araujo, John
    Campbell, Matthew T.
    Amaria, Rodabe
    Vokes, Natalie
    GASTROENTEROLOGY, 2023, 164 (06) : S1101 - S1101
  • [3] Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis.
    Wang, Yinghong
    Varatharajalu, Krishnavathana
    Shatila, Malek
    Junek, Kristin
    Ninoska, Ninoska Nataly
    Msaouel, Pavlos
    Campbell, Matthew T.
    Amaria, Rodabe Navroze
    Thomas, Anusha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis
    Klemm, Natasha
    Trasolini, Roberto
    Chahal, Daljeet
    Donnellan, Fergal
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (04)
  • [5] Vedolizumab Treatment of Refractory Immune Checkpoint Inhibitor Colitis
    McNally, Bridgette B.
    Sivakumar, Angiela
    Haddad, Nael
    Suchartlikitwong, Sakolwan
    Aguon, Paul Muna
    Fung, Brian M.
    Zucker, Kelly
    David, Joseph
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S756 - S756
  • [6] Efficacy of Infliximab and Vedolizumab in Immune Checkpoint Inhibitor Colitis: A Meta-Analysis
    Zuberi, Shaharyar
    Anderson, Kelsey
    Porth, Rachel
    Taneja, Vikas
    Feuerstein, Joseph D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S229 - S231
  • [7] Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
    Zhang, Zhe
    Zheng, Chang-Qing
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (29) : 10550 - 10558
  • [8] Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
    Zhang, Zhe
    Zheng, Chang-Qing
    FRONTIERS IN ONCOLOGY, 2022, 12 : 10550 - 10558
  • [9] Back to the Basics: Use Of Budesonide as the Treatment for Immune Checkpoint Inhibitor Induced Microscopic Colitis Non-Responsive to Prednisone, Infliximab, and Vedolizumab
    Kovach, Zach
    Shepherd, Katherine
    Cohen, Ethan M.
    Adekolu, Ayowumi
    Tandon, Kanwarpreet
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2002 - S2002
  • [10] Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
    Kaneoka, Ayaka
    Okada, Etsuko
    Sugino, Hitomi
    Saito-Sasaki, Natsuko
    Omoto, Daisuke
    Nakamura, Motonobu
    DIAGNOSTICS, 2022, 12 (02)
12345